The deal has analysts puzzled, as the US maker of Tylenol has seen sales dip after the White House linked it to autism.
The deal has analysts puzzled, as the US maker of Tylenol has seen sales dip after the White House linked the painkiller to autism.
By Reuters
Share
Save
Save articles to read later and create your own reading list.
Kimberly-Clark to buy Kenvue, maker of Tylenol, in $48 billion deal
Kimberly-Clark buys Tylenol-maker Kenvue in more than $40bn deal
Huggies Maker Buys Kenvue (Tylenol Maker) For $48 Billion
Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant
Kimberly-Clark to buy Kenvue in $48.7 billion deal
Kimberly-Clark acquista produttore Kenvue per 40 miliardi - Ultima ora - Ansa.it
Kimberly-Clark acquista produttore Kenvue per 40 miliardi - Notizie - Ansa.it
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
Kimberly-Clark agrees to purchase Kenvue for $48.7B - UPI.com
El dueño de Kleenex compra la empresa de Tylenol y Neutrógena por casi 35.000 millones
Kimberly-Clark is buying Kenvue, the maker of Tylenol, after months of controversy around whether the medicine is linked to…
The deal will unite two giants in the over-the-counter health business, bringing together brands like Kleenex and Benadryl.
President Donald Trump has claimed Kenvue’s pain reliever is a potential cause of autism, despite clear evidence.
The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol.
Kenvue's shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held.
Kimberly-Clark, il colosso a cui fanno capo i Kleenex e gli Huggies, ha raggiunto un accordo per acquistare Kenvue, la società…
